GRAZIANO: "Nivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis", 15 January 2016 (2016-01-15), pages 1 - 4, XP055603533, Retrieved from the Internet <URL:https://www.globenewswire.com/news-release/2016/01/15/802351/0/en/Nivalis-Therapeutics-Announces-FDA-Orphan-Drug-Designation-for-N91115-in-Cystic-Fibrosis.html> (C0)

WO-A2-2009/062118 (C0)

SCHWEITZER: "ProQR Announces Enrollment Has Started in Global Phase 1 b Study of QR-010 in Cystic Fibrosis Patients", MACDOUGALL BIOMEDICAL COMMUNICATIONS, 26 June 2015 (2015-06-26), pages 1 - 2, XP055487109, [retrieved on 20180112] (C0)

SMART, JANET: "Proteostasis Therapeutics Presents Preclinical Data for Its CFTR Amplifier Program at the 29th Annual North American Cystic Fibrosis Conference", MARKETWIRED, 8 October 2015 (2015-10-08), pages 1 - 2, XP009515115, Retrieved from the Internet <URL:https://web.archive.org/web/20180708090548/http://m.marketwired.com/press-release/proteostasis-therapeutics-inc-presents-preclinical-data-its-cftr-amplifier-program-29th-2062260.htm> [retrieved on 20180112] (C0)

SPYRYX: "Spyryx Biosciences to Present Safety, Stability & Effectiveness Data for SPX-101 at the North American Cystic Fibrosis Conference", SPYRYX BIOSCIENCES, 25 October 2016 (2016-10-25), Orlando, FL, pages 1 - 2, XP055487036, Retrieved from the Internet <URL:https://www.prnewswire.com/news-releases/spyryx-biosciences-to-present-safety-stability-effectiveness-data-for-spx-101-at-the-north-american-cystic-fibrosis-conference-october-27-29-2016-orlando-fl-300350083.html> [retrieved on 20180112] (C0)

US-A1- 2007 203 143 (C0)

US-A1- 2007 293 516 (C0)

US-A1- 2013 344 061 (C0)

WO-A1-2007/104944 (C0)

WO-A1-2014/060431 (C0)

WO-A1-2015/091532 (C0)

WO-A2-2004/100868 (C0)

WO-A2-2005/074603 (C0)

WO-A2-2007/114926 (C0)

KIM ET AL.: "The Protein Kinase 2 Inhibitor CX-4945 Induces Autophagy in Human Cancer Cell Lines", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 35, 2014, pages 2985 - 2989, XP055486635 (C0)